Analytical Data
-
Gene name
BTLA
- Application
-
Alternative Names
BTLA；B- and T-lymphocyte attenuator
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q7Z6A9
-
Expression Region
31-150aa
-
AA Sequence
KESCDVQLYI KRQSEHSILA GDPFELECPV YCANRPHVT WCKLNGTTCV KLEDRQTSWK EEKNISFFIL FEPVLPNDN GSYRCSANFQ SNLIESHSTT LYVTDVKSAS RPSKDEMAS
-
Molecular Weight
42 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BTLA (B and T Lymphocyte Attenuator) is an important immune checkpoint molecule expressed on various immune cells, including T and B lymphocytes. As a member of the CD28 superfamily, BTLA plays a crucial role in regulating immune responses by delivering inhibitory signals that can dampen T cell activation and proliferation. Research into BTLA has garnered significant interest due to its potential implications in autoimmune diseases, cancer immunotherapy, and organ transplantation. Dysregulation of BTLA signaling can lead to hyperactive immune responses, contributing to conditions such as rheumatoid arthritis and multiple sclerosis. Conversely, enhancing BTLA pathways may provide a strategy for improving immune tolerance and reducing graft rejection. The development of BTLA recombinant proteins is pivotal for advancing our understanding of its function and mechanisms. By creating well-characterized BTLA fusion proteins, researchers aim to elucidate the molecular interactions involved in BTLA signaling and to explore their therapeutic potential. This includes the potential use of BTLA as a target for monoclonal antibody therapies or as a biomarker for patient stratification in immunotherapies. Overall, the study of BTLA and its recombinant forms holds promise for contributing to novel therapeutic strategies in various immune-related conditions, highlighting the need for continued research in this area.
